Latest News Archive
Please select Category, Year, and then Month to display items
24 July 2024
|
Story Lacea Loader
![]()
The University of the Free State (UFS) is co-hosting the Global Social Innovation Indaba together with Social Innovation Exchange (SIX) on its Bloemfontein Campus from 30 September to 2 October 2024. This event brings together people from different sectors all over the world to discuss how to accelerate and support people-powered
change and create a better society for generations to come.
The UFS is excited to collaborate with SIX, as its vision and values overlap. During this three-day indaba, aspects such as – what it takes to build accountable, inclusive, and participatory institutions, specifically the future role of universities in South Africa – will be discussed. Themes to be explored include young people as drivers of change, post-industrial transitions and community resilience, the role of art, social change and bridging divides, and systemic approaches to dealing with unemployment.
Some of the speakers and participants in the programme include Carla Duprat from ICE (Brazil); Cheryl Jacob from ESquared Investments (South Africa); François Bonnici from the Schwab Foundation for Social Entrepreneurship (Switzerland); Sir Geoff Mulgan from the University College London (UCL) in the United Kingdom; and Dr Narissa Ramdhani from the Ifa Lethu Foundation (South Africa).
The UFS will also use the opportunity to showcase its campus and offerings to attendees, focusing on its transformation story and some of the interdisciplinary forward-thinking programmes. Guests will also be treated to true South African hospitality, laying the foundation for strong relationships and collaboration.
SIX believes in the transformative power of people working together. Exchanges based on mutual value and reciprocity are the missing link in tackling the world’s problems. As a friendly, expert entry point to global social innovation, their work connects organisations, sectors, communities, and nations to build capabilities and create opportunities for collaboration.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004